Legend Biotech Corp (LEGN) stock
LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.25+0.14 (+0.87%)
Close on Nov 18, 2026Market cap $3.01BP/E –Yield –
Legend Biotech revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Legend Biotech's revenue for the twelve months ending Jun 30, 2026 was $1.27B, up 59.5% year over year. For fiscal 2025 it was $1.03B, up 64.0% from the year before. The highest annual figure on record is $1.03B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.03B | +64.0% |
| FY2024 | Dec 31, 2024 | $627.30M | +120.0% |
| FY2023 | Dec 31, 2023 | $285.10M | +143.7% |
| FY2022 | Dec 31, 2022 | $117.01M | +70.0% |
| FY2021 | Dec 31, 2021 | $68.83M | -8.2% |
| FY2020 | Dec 31, 2020 | $75.00M | +25.0% |
| FY2019 | Dec 31, 2019 | $59.98M | +22.1% |
| FY2018 | Dec 31, 2018 | $49.13M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $387.50M | +51.9% |
| Q1 FY2026 | Mar 31, 2026 | $305.10M | +56.5% |
| Q4 FY2025 | Dec 31, 2025 | $306.38M | +64.2% |
| Q3 FY2025 | Sep 30, 2025 | $272.33M | +70.0% |
| Q2 FY2025 | Jun 30, 2025 | $255.10M | +36.8% |
| Q1 FY2025 | Mar 31, 2025 | $195.00M | +107.5% |
| Q4 FY2024 | Dec 31, 2024 | $186.58M | +134.9% |
| Q3 FY2024 | Sep 30, 2024 | $160.21M | +66.9% |
| Q2 FY2024 | Jun 30, 2024 | $186.52M | +154.4% |
| Q1 FY2024 | Mar 31, 2024 | $93.99M | +158.7% |
| Q4 FY2023 | Dec 31, 2023 | $79.42M | +187.4% |
| Q3 FY2023 | Sep 30, 2023 | $96.01M | +250.9% |
| Q2 FY2023 | Jun 30, 2023 | $73.33M | – |
| Q1 FY2023 | Mar 31, 2023 | $36.34M | – |
| Q4 FY2022 | Dec 31, 2022 | $27.63M | – |
| Q3 FY2022 | Sep 30, 2022 | $27.36M | – |
See a number that looks wrong?